Glen Eagle Advisors’s Definium Therapeutics DFTX Stock Holding History

Glen Eagle Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6	Closed	-$42	–	1101
2024 Q4	$42	Hold	6	–	–	﹤0.01%	1097
2024 Q3	$34	Hold	6	–	–	﹤0.01%	1147
2024 Q2	$43	Hold	6	–	–	﹤0.01%	1125
2024 Q1	$56	Hold	6	–	–	﹤0.01%	1087
2023 Q4	$22	Hold	6	–	–	﹤0.01%	1036
2023 Q3	$19	Sell	6 -24	-80%	-$99	﹤0.01%	1017
2023 Q2	$108	Hold	30	–	–	﹤0.01%	1041
2023 Q1	$95	Hold	30	–	–	﹤0.01%	1050
2022 Q4	$66	Sell	30 -22	-42%	-$61	﹤0.01%	1135
2022 Q3	$182	Sell	52 -1	-2%	-$10	﹤0.01%	1059
2022 Q2	$508	Buy	53 +24	+83%	+$304	﹤0.01%	940
2022 Q1	$481	Buy	+29	New	+$503	﹤0.01%	905
2021 Q3	–	Sell	-29	Closed	-$1.51K	–	1083
2021 Q2	$1.51K	Buy	+29	New	+$1.52K	﹤0.01%	951

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glen Eagle Advisors's DFTX Position: Q1 2025 in Review

Glen Eagle Advisors sold out of Definium Therapeutics (DFTX) in Q1 2025, closing a stake of 6 shares — an estimated $42 sold.

Glen Eagle Advisors first reported a position in DFTX in Q2 2021 and held it in 13 quarters. The position peaked at $1.51K in Q2 2021. 190 funds tracked by Wall St. Rank hold DFTX as of Q1 2025.

Glen Eagle Advisors reported no remaining Definium Therapeutics position as of Q1 2025 after selling out during the quarter.
Glen Eagle Advisors sold 6 Definium Therapeutics shares in Q1 2025, an estimated $42.
Glen Eagle Advisors first reported a position in Definium Therapeutics in Q2 2021 and held it in 13 quarters.
Glen Eagle Advisors's Definium Therapeutics position peaked at $1.51K in Q2 2021.
190 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2025.

Based on Glen Eagle Advisors's 13F filing for Q1 2025, filed 15 May 2025.